Peripherally Selective Pyrazoline CB1 Antagonists for Obesity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-obesity medications are ineffective in maintaining weight loss over time and often come with undesirable and dangerous side effects due to their inability to selectively target CB1 receptors in peripheral tissues while sparing brain receptors, leading to CNS-related adverse effects.
Innovation Solution
Development of novel pyrazoline compounds that act as CB1 receptor antagonists/inverse agonists with limited or no CNS adverse effects by preferentially targeting CB1 receptors in peripheral tissues, such as adipose tissue, liver, muscle, and gastrointestinal tract, while minimizing brain penetration to reduce CNS side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current anti-obesity medications are used to achieve weight loss, then weight reduction is achieved, but CNS-related adverse effects occur due to lack of selectivity between peripheral and brain CB1 receptors
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (such as bulky substituents at the R1 position or specific stereochemistry) that enable selective binding to peripheral CB1 receptors while reducing affinity for central CB1 receptors. This spatial differentiation in receptor interaction allows weight loss through peripheral mechanisms without activating central pathways that cause adverse effects.
Solution Approach 2:
The patent introduces peripherally-selective CB1 antagonists as intermediary agents that mediate weight loss through peripheral metabolic pathways without acting as direct mediators in central nervous system pathways. These compounds serve as selective intermediaries that decouple the therapeutic effect (peripheral metabolism) from the harmful effect (central side effects).
2Quantity of substance
If CB1 receptor antagonists are used to treat obesity, then appetite suppression and weight loss occur, but psychiatric and neurological side effects are produced
Solution Approach 1:
The patent employs local quality by creating compounds with modified molecular structures (such as indole, carbazole, or dibenzoxazole cores with specific substituents) that exhibit differential tissue distribution and receptor binding characteristics. These structural modifications ensure high affinity for peripheral CB1 receptors in adipose tissue, liver, and muscle while having reduced affinity for central CB1 receptors, thereby producing weight loss without psychiatric or neurological side effects.
Solution Approach 2:
The patent applies segmentation by separating the therapeutic function from the harmful function through molecular design. The compounds are structured to segment their receptor interaction profile, showing strong activity in peripheral tissues (adipose, liver, muscle) where CB1 blockade produces beneficial metabolic effects, while showing weak or no activity in central tissues where CB1 blockade produces adverse psychiatric and neurological effects.
3Quantity of substance
If existing anti-obesity drugs are used to reduce body weight, then initial weight loss occurs, but weight is not maintained over time
Solution Approach 1:
The patent applies continuity of useful action by developing compounds with high metabolic stability and sustained pharmacological activity. The peripherally-selective CB1 antagonists are designed to maintain consistent therapeutic levels in peripheral tissues over extended periods, ensuring continuous blockade of CB1 receptors in adipose tissue, liver, and muscle. This continuous peripheral action maintains sustained weight loss and prevents weight regain, addressing the limitation of existing drugs that fail to maintain efficacy over time.
Data Source
AI summary
The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.